Comparison of 3rd line immune checkpoint inhibitors to irinotecan-based chemotherapy in patient with refractory to paclitaxel plus ramucirumab : multi-center, observational study
- Conditions
- Neoplasms
- Registration Number
- KCT0007732
- Lead Sponsor
- Soon Chun Hyang University Hospital Bucheon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
1) 19 years of age or older
2) Histologically confirmed gastric adenocarcinoma
3) Patients who have been treated with weekly paclitaxel and ramucirumab combination therapy as palliative second-line systemic chemotherapy, or who have relapsed during or within 6 months of XELOX adjuvant chemotherapy after surgery and have been treated with weekly paclitaxel and ramucirumab
4) Patients who have received immune checkpoint chemotherapy (nivolumab or pembrolizumab) or irinotecan-based cytotoxic chemotherapy (irinotecan alone or FOLFIRI therapy) as third-line chemotherapy
5) Patients who received fluropyrimidine plus platinum+/-trastuzumab as primary anticancer treatment
1) Patients who have metastatic cancer other than stomach cancer
2) Patients treated with irinotecan, nivolumab, or pembrolizumab as first-line or second-line palliative chemotherapy
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall suvival
- Secondary Outcome Measures
Name Time Method Progression-free survival, overall response rate, adverse events